Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3070866 | 0.99 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL2874321 | 0.85 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL2874323 | 0.85 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL19709415 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL656202 | 0.84 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL3058168 | 0.81 | HTR2C (0.46) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL1639581 | 0.78 | HTR2C (0.48) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL1639584 | 0.78 | HTR2C (0.48) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL1639678 | 0.78 | HTR2C (0.48) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL13066510 | 0.77 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | SLC6A2 4355/4885SLC6A4 3722/4885SLC6A3 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.